These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 31649854)

  • 21. Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer.
    Mei D; Chen B; He B; Liu H; Lin Z; Lin J; Zhang X; Sun N; Zhao L; Wang X; Zhang Q
    Acta Pharm Sin B; 2019 Sep; 9(5):1061-1077. PubMed ID: 31649854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bionano interactions of mcf-7 breast tumor cells with a transferrin receptor targeted nanoparticle.
    Du W; Fan Y; He B; Zheng N; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Mol Pharm; 2015 May; 12(5):1467-76. PubMed ID: 25811613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer.
    Gao W; Ye G; Duan X; Yang X; Yang VC
    Int J Nanomedicine; 2017; 12():1047-1064. PubMed ID: 28223798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery.
    Du W; Fan Y; Zheng N; He B; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2013 Jan; 34(3):794-806. PubMed ID: 23103156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade.
    Mishra GP; Nguyen D; Alani AW
    Mol Pharm; 2013 May; 10(5):2071-8. PubMed ID: 23590802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing the Delivery of Chemotherapeutics: Role of Biodegradable Polymeric Nanoparticles.
    Ahlawat J; Henriquez G; Narayan M
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30150595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTOR and Tumor Cachexia.
    Duval AP; Jeanneret C; Santoro T; Dormond O
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking Autophagic Flux Enhances Iron Oxide Nanoparticle Photothermal Therapeutic Efficiency in Cancer Treatment.
    Ren X; Chen Y; Peng H; Fang X; Zhang X; Chen Q; Wang X; Yang W; Sha X
    ACS Appl Mater Interfaces; 2018 Aug; 10(33):27701-27711. PubMed ID: 30048114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor mediated transcytosis in biological barrier: The influence of receptor character and their ligand density on the transmembrane pathway of active-targeting nanocarriers.
    Song X; Li R; Deng H; Li Y; Cui Y; Zhang H; Dai W; He B; Zheng Y; Wang X; Zhang Q
    Biomaterials; 2018 Oct; 180():78-90. PubMed ID: 30025247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review.
    Muhamad N; Plengsuriyakarn T; Na-Bangchang K
    Int J Nanomedicine; 2018; 13():3921-3935. PubMed ID: 30013345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combined therapeutic effects of
    Liu Q; Qian Y; Li P; Zhang S; Wang Z; Liu J; Sun X; Fulham M; Feng D; Chen Z; Song S; Lu W; Huang G
    Acta Pharm Sin B; 2018 May; 8(3):371-380. PubMed ID: 29881676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinational strategy for high-performance cancer chemotherapy.
    Qin SY; Cheng YJ; Lei Q; Zhang AQ; Zhang XZ
    Biomaterials; 2018 Jul; 171():178-197. PubMed ID: 29698868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Robust Anticancer Efficacy of a Biologically Synthesized Tumor Acidity-Responsive and Autophagy-Inducing Functional Beclin 1.
    Ding GB; Sun J; Wu G; Li B; Yang P; Li Z; Nie G
    ACS Appl Mater Interfaces; 2018 Feb; 10(6):5227-5239. PubMed ID: 29359549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zebrafish: A Visual Model To Evaluate the Biofate of Transferrin Receptor-Targeted 7Peptide-Decorated Coumarin 6 Micelles.
    Li Y; Song X; Yi X; Wang R; Lee SM; Wang X; Zheng Y
    ACS Appl Mater Interfaces; 2017 Nov; 9(44):39048-39058. PubMed ID: 29039926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
    Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
    Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
    Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
    Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.